WFA
RLMD icon

Wipfli Financial Advisors’s Relmada Therapeutics RLMD Stock Holding History

Wipfli Financial Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$5K Buy
+139
New +$3.85K ﹤0.01% 2093

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wipfli Financial Advisors's RLMD Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Relmada Therapeutics (RLMD) in Q3 2022: 139 shares worth $5K. The stake represents ﹤0.01% of the portfolio and ranks #2093 among its holdings.

134 funds tracked by Wall St. Rank hold RLMD as of Q3 2022.

  • Wipfli Financial Advisors held 139 shares of Relmada Therapeutics worth $5K as of Q3 2022.
  • Relmada Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
  • Relmada Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2093 holding.
  • 134 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.